[go: up one dir, main page]

MA43963A - Composé de pipéridine substituée et son utilisation - Google Patents

Composé de pipéridine substituée et son utilisation

Info

Publication number
MA43963A
MA43963A MA043963A MA43963A MA43963A MA 43963 A MA43963 A MA 43963A MA 043963 A MA043963 A MA 043963A MA 43963 A MA43963 A MA 43963A MA 43963 A MA43963 A MA 43963A
Authority
MA
Morocco
Prior art keywords
piperidine compound
substituted piperidine
substituted
compound
piperidine
Prior art date
Application number
MA043963A
Other languages
English (en)
Inventor
Tatsuhiko Fujimoto
Koichiro Fukuda
Mariko HIROZANE
Takahiro Matsumoto
Kentaro Rikimaru
Hiromichi Sugimoto
Norihito Tokunaga
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA43963A publication Critical patent/MA43963A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA043963A 2016-02-04 2017-02-01 Composé de pipéridine substituée et son utilisation MA43963A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016019834 2016-02-04

Publications (1)

Publication Number Publication Date
MA43963A true MA43963A (fr) 2018-12-12

Family

ID=58054473

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043963A MA43963A (fr) 2016-02-04 2017-02-01 Composé de pipéridine substituée et son utilisation

Country Status (36)

Country Link
US (6) US10508083B2 (fr)
EP (3) EP3411358B1 (fr)
JP (1) JP6609060B2 (fr)
KR (1) KR102734774B1 (fr)
CN (2) CN114181136A (fr)
AR (1) AR107519A1 (fr)
AU (1) AU2017215021B2 (fr)
BR (1) BR112018015574B1 (fr)
CA (1) CA3013428C (fr)
CL (1) CL2018002099A1 (fr)
CO (1) CO2018008705A2 (fr)
CY (1) CY1125003T1 (fr)
DK (2) DK3411358T3 (fr)
EA (1) EA036166B1 (fr)
EC (1) ECSP18066504A (fr)
ES (2) ES2907373T3 (fr)
FI (1) FI3984994T3 (fr)
HR (2) HRP20241334T1 (fr)
HU (2) HUE068362T2 (fr)
IL (1) IL260835B (fr)
LT (2) LT3411358T (fr)
MA (1) MA43963A (fr)
MX (1) MX382435B (fr)
MY (1) MY186905A (fr)
PH (1) PH12018501666B1 (fr)
PL (2) PL3984994T3 (fr)
PT (2) PT3984994T (fr)
RS (2) RS65984B1 (fr)
SG (1) SG11201806429PA (fr)
SI (2) SI3411358T1 (fr)
TN (1) TN2018000262A1 (fr)
TW (2) TW202220959A (fr)
UA (1) UA122433C2 (fr)
UY (1) UY37103A (fr)
WO (1) WO2017135306A1 (fr)
ZA (1) ZA201805544B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3984994T (pt) * 2016-02-04 2024-10-10 Takeda Pharmaceuticals Co Composto de piperidina substituída como agonista de orexina tipo 2 para o tratamento da narcolepsia
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP6957598B2 (ja) 2017-03-08 2021-11-02 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
EP3663281B1 (fr) * 2017-08-03 2022-12-28 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son application
UA125597C2 (uk) 2017-08-03 2022-04-27 Такеда Фармасьютікал Компані Лімітед Гетероциклічна сполука та її застосування
EP3725780B1 (fr) 2017-12-12 2023-03-01 University of Tsukuba Dérivé de sulfonamide ou sel d'addition d'acide pharmaceutiquement acceptable
EA039459B1 (ru) * 2017-12-25 2022-01-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение в качестве средства для лечения заболеваний, связанных с рецептором орексина 2 типа
US11655241B2 (en) 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP3816154B1 (fr) * 2018-06-29 2025-04-23 Takeda Pharmaceutical Company Limited Composé hétérocyclique et son application
US12071434B2 (en) 2018-12-12 2024-08-27 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3896060B1 (fr) 2018-12-12 2023-08-16 Takeda Pharmaceutical Company Limited Composé hétérocyclique
CN118420600A (zh) 2019-01-31 2024-08-02 武田药品工业株式会社 杂环化合物及其用途
WO2020167706A1 (fr) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine
WO2020167701A1 (fr) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine de type pyrrolidine
WO2021026047A1 (fr) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle
BR112022004587A2 (pt) * 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Métodos para tratar narcolepsia tipo 1, diminuir eventos tipo cataplexia, aumentar concentração de cálcio intracelular, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, tratar uma doença associada a nível de orexina reduzido, aumentar alerta, melhorar classificação de escala de sonolência epworth, e, composição farmacêutica
CA3154320A1 (fr) 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Utilisation d'un agoniste du recepteur de l'orexine 2 pour le traitement d'une somnolence excessive
EP4065585B1 (fr) * 2019-11-25 2025-08-20 Alkermes, Inc. Composés macrocycliques substitués et méthodes de traitement associées
US11352357B2 (en) 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
BR112022009861A2 (pt) 2019-11-27 2022-08-02 Sumitomo Pharma Co Ltd Derivado de cicloalquil ureia
JP7665527B2 (ja) * 2019-11-27 2025-04-21 武田薬品工業株式会社 複素環化合物
US20230029486A1 (en) * 2020-01-10 2023-02-02 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450
PE20231384A1 (es) 2020-08-18 2023-09-12 Merck Sharp And Dohme Llc Agonistas de bicicloheptano pirrolidina de los receptores de orexina
US12497362B2 (en) 2020-08-18 2025-12-16 Merck Sharp & Dohme Llc Cyclopentapyrrole orexin receptor agonists
JP2022064180A (ja) * 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
WO2022109117A1 (fr) * 2020-11-23 2022-05-27 Merck Sharp & Dohme Corp. Agonistes du récepteur de l'orexine de type 3-amino pyrrolidine et pipéridine macrocyclique
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
AR125073A1 (es) 2021-03-12 2023-06-07 Takeda Pharmaceuticals Co Uso de un agonista del receptor de orexina 2 para el tratamiento de una enfermedad o trastorno mediados por orexina
US20240165092A1 (en) 2021-04-02 2024-05-23 Takeda Pharmaceutical Limited Company Use of an orexin 2 receptor agonist for post operation recovery
CA3215210A1 (fr) * 2021-04-26 2022-11-03 Younggi Choi Composes macrocycliques d'amide substitues ayant une activite agoniste du recepteur de l'orexine 2
AU2022269811A1 (en) * 2021-05-03 2023-11-16 Jazz Pharmaceuticals Ireland Limited Orexin receptor agonists and uses thereof
EP4353309A4 (fr) 2021-05-26 2025-05-07 Sumitomo Pharma Co., Ltd. Dérivé de phényle urée
CN117999265A (zh) * 2021-05-26 2024-05-07 阿尔克姆斯有限公司 取代的融合双环大环化合物及其相关治疗方法
WO2022251304A1 (fr) 2021-05-26 2022-12-01 Alkerme, Inc. Composés macrocycliques de carbamate substitués et méthodes de traitement associées
JP7668768B2 (ja) * 2021-05-26 2025-04-25 住友ファーマ株式会社 シクロアルキルウレア誘導体を含有する医薬組成物
WO2023199091A1 (fr) 2022-04-12 2023-10-19 Takeda Pharmaceutical Company Limited Composé hétérocyclique
TW202404962A (zh) 2022-04-22 2024-02-01 日商住友製藥股份有限公司 雙環胺甲醯胺衍生物
EP4543447A2 (fr) * 2022-06-21 2025-04-30 Alkermes, Inc. Composés bicycliques fusionnés substitués et méthodes de traitement associées
EP4543446A1 (fr) * 2022-06-21 2025-04-30 Alkermes, Inc. Composés bicycliques fusionnés substitués et procédés de traitement associés
CA3260215A1 (fr) * 2022-06-21 2023-12-28 Alkermes, Inc. Composés pyrrolidinyle et pipéridinyle substitués et méthodes de traitement associées
IL319940A (en) 2022-10-07 2025-05-01 Kissei Pharmaceutical Cyclopentane compound
WO2024095158A1 (fr) 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosage d'agonistes du récepteur de type 2 de l'orexine
JP7592226B1 (ja) 2022-10-31 2024-11-29 武田薬品工業株式会社 複素環化合物
AU2023403030A1 (en) 2022-11-30 2025-06-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
AU2023395547A1 (en) 2022-12-16 2025-06-26 Daiichi Sankyo Company, Limited 2-azabicyclo[3.1.1]heptane compound
IL322817A (en) 2023-03-16 2025-10-01 Takeda Pharmaceuticals Co Macrocyclic heterocyclic compounds and their uses
TW202502342A (zh) * 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途
WO2025124698A1 (fr) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Dérivés d'arylsulfone et de sulfanone utilisés en tant que modulateurs du récepteur de l'orexine
WO2025132542A1 (fr) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Agonistes macrocycliques de l'orexine
WO2025211416A1 (fr) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 Composé macrocyclique de sulfonamide substitué
WO2025211415A1 (fr) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 Composé sulfonamide substitué
WO2025224168A1 (fr) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Dérivés d'arylsulfone et de sulfanone utilisés en tant que modulateurs du récepteur de l'orexine
WO2025229493A1 (fr) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosage d'agonistes du récepteur de l'orexine de type 2
WO2025229494A1 (fr) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Composé hétérocyclique
WO2025229492A1 (fr) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Microcapsules agonistes du récepteur de type 2 de l'orexine pour dosage à libération prolongée
WO2025229495A1 (fr) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Composé hétérocyclique

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608602A1 (fr) 1986-12-23 1988-06-24 Cerm Cent Europ Rech Mauvernay Nouvelles 3-piperidineamines ou 3-azepineamines substituees, leur preparation et leurs applications en therapeutique
SE9003652D0 (sv) 1990-11-15 1990-11-15 Astra Ab New heterocyclic compounds
CA2214247C (fr) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de substances amyloides
ES2203793T3 (es) 1996-03-15 2004-04-16 Novartis Ag N-7-heterociclil-pirrolo(2,3-d)pirimidinas y su empleo.
ATE298765T1 (de) 1996-08-27 2005-07-15 Praecis Pharm Inc Beta-amyloid peptidaggregation regulierende peptide mit d-aminosäuren
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
DE60045005D1 (de) 1999-06-28 2010-11-04 Oklahoma Med Res Found Inhibitoren des memapsin 2 und ihre verwendung
AU6615300A (en) 1999-07-30 2001-02-19 Board Of Trustees Of The Leland Stanford Junior University Hypocretin and hypocretin receptors in regulation of sleep and related disorders
AU2001251306A1 (en) 2000-04-04 2001-10-15 Siegel, Jerome M. Treatment of sleep disorders with hypocretin-1
CA2498264A1 (fr) 2002-09-09 2004-05-13 Nura, Inc. Recepteurs couples a la proteine g et leurs utilisations
DE60320302T2 (de) 2002-12-13 2009-05-20 Janssen Pharmaceutica N.V. Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
US20110053859A1 (en) 2007-10-10 2011-03-03 The U. S. Government Respresented by the Department of Veterans Affairs Methods to reduce the effects of sleep deprivation
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
JP2013523642A (ja) 2010-03-26 2013-06-17 メルク・シャープ・エンド・ドーム・コーポレイション グルカゴン受容体拮抗薬としての新規なスピロイミダゾロン誘導体、組成物およびそれらの使用方法
JP5976011B2 (ja) * 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
JP2014520876A (ja) 2011-07-20 2014-08-25 ウニヴェルシテ ピエール エ マリー キュリー（パリ ６） イミノ糖ｃ−グリコシド、その製造および使用
BR112015000176A2 (pt) * 2012-07-03 2017-06-27 Heptares Therapeutics Ltd antagonistas do receptor de orexina
WO2014170343A1 (fr) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Agents de dépolarisation et modulateurs du récepteur nicotinique de l'acétylcholine pour le traitement de troubles dopaminergiques
WO2014198880A1 (fr) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. Composés 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-diones ayant une activité agoniste des récepteurs des orexines de type 2
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
US10172916B2 (en) 2013-11-15 2019-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
US9815787B2 (en) 2013-12-12 2017-11-14 University Of Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
SG10201900536TA (en) 2014-03-06 2019-02-27 Shanghai Haiyan Pharmaceutical Tech Co Ltd Piperidine derivatives as orexin receptor antagonist
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
EP3029024A1 (fr) 2014-12-02 2016-06-08 Ferrer Internacional, S.A. Composés de 2-(2-aminophénoxy)-3-chloronaphthalène-1,4-dione présentant une activité d'agoniste du récepteur d'orexine 2
WO2016133160A1 (fr) 2015-02-19 2016-08-25 国立大学法人筑波大学 Dérivé de sulfamide ou sel d'addition d'acide pharmaceutiquement acceptable correspondant
JP6189905B2 (ja) 2015-09-30 2017-08-30 株式会社スクウェア・エニックス ビデオゲーム処理プログラム、及びビデオゲーム処理システム
PT3984994T (pt) 2016-02-04 2024-10-10 Takeda Pharmaceuticals Co Composto de piperidina substituída como agonista de orexina tipo 2 para o tratamento da narcolepsia

Also Published As

Publication number Publication date
AU2017215021A1 (en) 2018-08-30
EP3984994A1 (fr) 2022-04-20
BR112018015574B1 (pt) 2023-11-28
EP4438041A2 (fr) 2024-10-02
CA3013428C (fr) 2024-02-13
US20200115399A1 (en) 2020-04-16
WO2017135306A1 (fr) 2017-08-10
JP6609060B2 (ja) 2019-11-20
RS65984B1 (sr) 2024-10-31
TW201731817A (zh) 2017-09-16
US20170226137A1 (en) 2017-08-10
MX382435B (es) 2025-03-13
ECSP18066504A (es) 2018-10-31
CY1125003T1 (el) 2023-01-05
ES2991028T3 (es) 2024-12-02
HRP20220127T1 (hr) 2022-04-15
IL260835A (en) 2019-02-28
TW202220959A (zh) 2022-06-01
US10287305B2 (en) 2019-05-14
MX2018009494A (es) 2018-09-06
PH12018501666B1 (en) 2023-05-26
US10898737B2 (en) 2021-01-26
SI3984994T1 (sl) 2024-12-31
US10508083B2 (en) 2019-12-17
HRP20241334T1 (hr) 2025-01-03
PT3984994T (pt) 2024-10-10
US20220081399A1 (en) 2022-03-17
DK3411358T3 (da) 2022-01-17
US20190031611A1 (en) 2019-01-31
ZA201805544B (en) 2019-11-27
KR102734774B1 (ko) 2024-11-26
UA122433C2 (uk) 2020-11-10
US20240174610A1 (en) 2024-05-30
SG11201806429PA (en) 2018-08-30
PL3984994T3 (pl) 2024-11-04
EP3411358B1 (fr) 2021-11-24
AU2017215021B2 (en) 2020-07-23
SI3411358T1 (sl) 2022-04-29
HUE057696T2 (hu) 2022-05-28
AR107519A1 (es) 2018-05-09
BR112018015574A2 (pt) 2018-12-26
TN2018000262A1 (en) 2020-01-16
CN108884043A (zh) 2018-11-23
TWI755374B (zh) 2022-02-21
PL3411358T3 (pl) 2022-02-28
US11292766B2 (en) 2022-04-05
EA201891742A1 (ru) 2019-01-31
PH12018501666A1 (en) 2019-06-17
MY186905A (en) 2021-08-26
CA3013428A1 (fr) 2017-08-10
EP4438041A3 (fr) 2025-01-01
CO2018008705A2 (es) 2018-11-13
CL2018002099A1 (es) 2018-11-09
DK3984994T3 (da) 2024-10-14
LT3984994T (lt) 2024-10-10
IL260835B (en) 2021-10-31
ES2907373T3 (es) 2022-04-25
LT3411358T (lt) 2022-04-25
CN108884043B (zh) 2021-11-26
UY37103A (es) 2017-08-31
CN114181136A (zh) 2022-03-15
RS62861B1 (sr) 2022-02-28
US20190263843A1 (en) 2019-08-29
KR20180103985A (ko) 2018-09-19
EP3411358A1 (fr) 2018-12-12
EA036166B1 (ru) 2020-10-08
NZ745259A (en) 2025-03-28
FI3984994T3 (fi) 2024-10-03
US12281073B2 (en) 2025-04-22
HUE068362T2 (hu) 2024-12-28
EP3984994B1 (fr) 2024-07-03
JP2019504098A (ja) 2019-02-14
PT3411358T (pt) 2022-01-19

Similar Documents

Publication Publication Date Title
MA43963A (fr) Composé de pipéridine substituée et son utilisation
EP3663281A4 (fr) Composé hétérocyclique et son application
EP3816153A4 (fr) Composé hétérocyclique et son utilisation
EP3554630C0 (fr) Dispositif de défibrillateur externe automatique
MA39732A (fr) Composé de cyclopropanamine et son utilisation
EP3366684A4 (fr) Composé hétérocyclique
EP3438109A4 (fr) Composé hétérocyclique
EP3020714A4 (fr) Composé imidazole-dicétone et son utilisation
EP3521301A4 (fr) Composé polyamide et son utilisation
EP2963027A4 (fr) Composé tricyclique et son utilisation
EP3372594A4 (fr) Dérivé pyrimidine et son utilisation
EP3312162A4 (fr) Composé de diarylazole et pesticide
EP3327019A4 (fr) Composé hétérocyclique
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
MA52033A (fr) Composé de diarylimidazole et agent de lutte antiparasitaire
EP3366679A4 (fr) Composé hétérocyclique
EP3681877A4 (fr) Composé dérivé de pyrazole et son utilisation
EP3533799A4 (fr) Composé
EP2985283A4 (fr) Composé anti-angiogenèse, intermédiaire et son utilisation
EP3438103A4 (fr) Composé de griséofulvine
EP3404023A4 (fr) Composé bihétérocyclique
EP3424905A4 (fr) Composé hétérocyclique
EP3511320A4 (fr) Composé cyclique
MA52214A (fr) Composé hétérocyclique et son utilisation
DK3672967T3 (da) Azaindolylpyridon- og diazaindolylpyridonforbindelser